This page shows the latest Opsumit news and features for those working in and with pharma, biotech and healthcare.
Pomalyst, followed by Actelion with 26 inquiries mainly for pulmonary artery hypertension drugs Tracleer and Opsumit.
Opsumit (macitentan) and Uptravi (selexipag).
Actelion has revealed that a late-stage trial of Opsumit in patients with Eisenmenger syndrome failed to meet its objectives, just as it is immersed in takeover talks with Johnson &Johnson ... Overall, it could reduce Opsumit's sales potential by around
drugs Opsumit (macitentan) and Uptravi (selexipag.
for follow-up PAH drugs Opsumit (macitentan) and Uptravi (selexipag), which are predicted to bring in combined sales of $4bn-plus by 2020.
$782m). However, follow-up Opsumit (macitentan), which launched in 2013, is still very much in the growth phase – rising 68% to CHF 596m in the first nine months – while new launch ... Meanwhile, Opsumit has plenty of room to grow with sales expected
More from news
Approximately 7 fully matching, plus 10 partially matching documents found.
At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag). ... He also led and managed the highly successful launches of Opsumit,
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...